Search Within

Neeta Pandit-Taskar

Formats
  1. Meeting Abstract (157)
  2. Journal Article (144)
  3. Review (20)
  4. Book Section (17)
  5. Guidelines (5)
  6. Editorial (2)
Groups
  1. Molecular Imaging and Therapy Service (345)
  2. Radiology, Department of (345)
  3. GSK Faculty (145)
  4. Medical Physics (128)
  5. Department of Medicine (122)
  6. Molecular Pharmacology and Chemistry Program Faculty (103)

More Groups

People
  1. Steven Larson (99)
  2. Jorge Carrasquillo (77)
  3. Pat Zanzonico (58)
  4. Serge Lyashchenko (53)
  5. Jason Lewis (52)
  6. Kim Kramer (51)

More People

Years
  1. 2025 (7)
  2. 2024 (22)
  3. 2023 (31)
  4. 2022 (33)
  5. 2021 (21)
  6. 2020 (12)

More Years

Publications
  1. Journal of Nuclear Medicine (67)
  2. Journal of Clinical Oncology (48)
  3. European Journal of Nuclear Medicine and Molecular Imaging (21)
  4. Pediatric Blood and Cancer (21)
  5. Neuro-Oncology (20)
  6. Blood (14)

More Publications

Publishers
  1. Society of Nuclear Medicine (67)
  2. Springer (49)
  3. American Society of Clinical Oncology (48)
  4. Elsevier Inc. (38)
  5. Oxford University Press (23)
  6. Wiley Periodicals, Inc (21)

More Publishers

Results (345)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Programmed death ligand-1 PET imaging in patients with melanoma: A pilot study
    Journal Article

    Pandit-Taskar, N.; Mauguen, A.; Frosina, D.; Jungbluth, A.; Busam, K. J.; Lyashchenko, S.; Schwartz, J.; Momtaz, P.; Warner, A. B.; Smithy, J. W.; more...
    Melanoma Research (2025)

    Fulltext@MSK | Save
  • Determination of the intralesional distribution of theranostic (124)I-Omburtamab convection-enhanced delivery in treatment of diffuse intrinsic pontine glioma
    Journal Article

    Velo, A. F.; Larsen, A. G.; Humm, J. L.; Zanzonico, P.; Haque, S.; Souweidane, M.; Pandit-Taskar, N.
    Journal of Nuclear Medicine (2025)

    Fulltext@MSK | Save
  • Computational nuclear oncology toward precision radiopharmaceutical therapies: Ethical, regulatory, and socioeconomic dimensions of theranostic digital twins
    Journal Article

    Strigari, L.; Schwarz, J.; Bradshaw, T.; Brosch-Lenz, J.; Currie, G.; El-Fakhri, G.; Jha, A. K.; Mežinska, S.; Pandit-Taskar, N.; Roncali, E.; more...
    Journal of Nuclear Medicine (2025)

    Fulltext@MSK | Save
  • STARLITE 2: Phase 2 study of nivolumab plus (177)lutetium-labeled anti-carbonic anhydrase IX (CAIX) monoclonal antibody girentuximab ((177)Lu-girentuximab) in patients with advanced clear cell renal cell carcinoma (ccRCC)
    Meeting Abstract

    Feldman, D. R.; Motzer, R. J.; Knezevic, A.; Voss, M. H.; Lyashchenko, S. K.; Park, H.; Larson, S. M.; Pandit-Taskar, N.
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Computational nuclear oncology toward precision radiopharmaceutical therapies: Current tools, techniques, and uncharted territories
    Review

    Yusufaly, T.; Roncali, E.; Brosch-Lenz, J.; Uribe, C.; Jha, A. K.; Currie, G.; Dutta, J.; El-Fakhri, G.; McMeekin, H.; Pandit-Taskar, N.; more...
    Journal of Nuclear Medicine (2025)

    Fulltext@MSK | Save
  • Safety observations in neuroblastoma patients undergoing (18)F- mFBG PET
    Journal Article

    Pandit-Taskar, N.; Basu, E.; Balquin, E.; Mozley, P. D.; Jacobson, A. F.; Modak, S.
    Nuclear Medicine Communications (2025)

    Fulltext@MSK | Save
  • FAP-targeted SPECT/CT and PET/CT imaging for breast cancer patients
    Review

    McGale, J.; Khurana, S.; Howell, H.; Nakhla, A.; Roa, T.; Doshi, P.; Shirini, D.; Huang, A.; Duong, P.; Backhaus, P.; more...
    Clinical Nuclear Medicine (2025)

    Fulltext@MSK | Save
  • CD38-SADA pretargeted radioimmunotherapy (PRIT) with Lutetium 177 (Lu177)-DOTA in adult patients with relapsed or refractory non-Hodgkin lymphoma: A first-in-human phase 1 trial
    Meeting Abstract

    Zain, J.; Wong, J.; Horwitz, S.; Pandit-Taskar, N.; Al-Janadi, A.; Mancini, B.; Khawaja, R.; Lee, C. Y.; Howansky, A.; Liles, D.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Phase 1 dose finding study evaluating the safety, tolerability, and efficacy of iopofosine I 131 in children, adolescents, and young adults with inoperable relapsed or refractory high-grade gliomas: A trial-in-progress
    Meeting Abstract

    Sait, S. F.; Morgenstern, D. A.; Pandit-Taskar, N.; Das, A.; Pudel, M.; Fisher, C.; Zanzonico, P.; Haque, S.; Longcor, J.; Shustov, A.; more...
    Neuro-Oncology (2024)

    Fulltext@MSK | Save
  • Survival outcomes and dosimetric analysis of Iomab-B (131I-apamistamab) followed by allogeneic hematopoietic cell transplant for patients with TP53 mutated relapsed/refractory AML
    Meeting Abstract

    Natwa, M.; Leung, E.; Chen, M. K.; Wagner, R.; Yap, W.; Griffeth, L.; Wiseman, G.; Wahl, R.; Avril, N.; Lamonica, D.; more...
    Journal of Nuclear Medicine (2024)

    Fulltext@MSK | Save